Please assess the completion status of the following clinical trial:

Trial Title: Ticagrelor for PCI Post Thrombolysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years and over.~2. Planned PCI between 4-24 hours after administration of fibrinolytic therapy for STEMI.~3. Treatment with aspirin and clopidogrel as an adjunct to fibrinolytic therapy.~4. Informed written consent.~Exclusion Criteria:~1. Atrial fibrillation or need for systemic anticoagulation therapy.~2. Prior PCI or coronary artery bypass grafting during past 3 months.~3. Active bleeding or high risk of bleeding based upon clinical assessment.~4. Known severe liver or renal disease or patient requiring dialysis.~5. Concomitant oral or IV therapy with strong cytochrome (CYP3A) inhibitors which cannot be stopped.~6. Contraindication to ticagrelor or clopidogrel.~7. Planned surgery during the study period.~8. Any of the following in the absence of a functioning implanted pacemaker: sick sinus syndrome, 2nd or 3rd degree AVB, documented syncope of suspected bradycardic origin.~9. Known clinically important thrombocytopenia or anemia.~10. Known pregnancy or lactation.~11. Condition which may either put the patient at risk or influence the result of the study.~12. Previous randomization in this SETFAST study.~13. Participation in another clinical study with an investigational product or device study over the past 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clopidogrel arm (Type: ACTIVE_COMPARATOR): Clopidogrel 300 mg before PCI followed by 75 mg po OD
- Ticagrelor arm (Type: EXPERIMENTAL): Ticagrelor 180 mg before PCI followed by 90 mg po BID

Based on this trial design, predict the completion outcome and termination type (if applicable).